Barinthus Biotherapeutics PLC Sponsored ADR (BRNS)
(Delayed Data from NSDQ)
$2.21 USD
-0.05 (-2.21%)
Updated May 24, 2024 03:27 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
BRNS 2.21 -0.05(-2.21%)
Will BRNS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BRNS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BRNS
Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
BRNS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates
The Joint Corp. (JYNT) Q4 Earnings and Revenues Top Estimates
Other News for BRNS
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024
Barinthus Biotherapeutics to present VTP-300 data updates at EASL Congress 2024
Barinthus price target lowered to $11 from $12 at Alliance Global Partners
Buy Rating for Barinthus Biotherapeutics Backed by Strong Financials and Promising Clinical Trials
Analysts Offer Insights on Healthcare Companies: Barinthus Biotherapeutics (BRNS) and GoodRx Holdings (GDRX)